Wave Life Sciences Ltd.

DB:1U5 Stock Report

Market Cap: €1.6b

Wave Life Sciences Management

Management criteria checks 2/4

Wave Life Sciences' CEO is Paul B. Bolno, appointed in Dec 2013, has a tenure of 11.17 years. total yearly compensation is $3.87M, comprised of 16.4% salary and 83.6% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth €2.23M. The average tenure of the management team and the board of directors is 4.5 years and 8.3 years respectively.

Key information

Paul B. Bolno

Chief executive officer

US$3.9m

Total compensation

CEO salary percentage16.4%
CEO tenure11.2yrs
CEO ownership0.1%
Management average tenure4.5yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul B. Bolno's remuneration changed compared to Wave Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$143m

Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$62m

Dec 31 2023US$4mUS$636k

-US$58m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

-US$131m

Mar 31 2023n/an/a

-US$151m

Dec 31 2022US$3mUS$618k

-US$162m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$120m

Mar 31 2022n/an/a

-US$118m

Dec 31 2021US$4mUS$597k

-US$122m

Sep 30 2021n/an/a

-US$116m

Jun 30 2021n/an/a

-US$143m

Mar 31 2021n/an/a

-US$145m

Dec 31 2020US$1mUS$579k

-US$150m

Sep 30 2020n/an/a

-US$178m

Jun 30 2020n/an/a

-US$196m

Mar 31 2020n/an/a

-US$197m

Dec 31 2019US$4mUS$579k

-US$194m

Sep 30 2019n/an/a

-US$175m

Jun 30 2019n/an/a

-US$162m

Mar 31 2019n/an/a

-US$156m

Dec 31 2018US$6mUS$541k

-US$147m

Compensation vs Market: Paul B.'s total compensation ($USD3.87M) is above average for companies of similar size in the German market ($USD1.50M).

Compensation vs Earnings: Paul B.'s compensation has increased whilst the company is unprofitable.

CEO

Paul B. Bolno (50 yo)

11.2yrs

Tenure

US$3,874,300

Compensation

Dr. Paul B. Bolno, M.D., MBA served as an Independent Director at SQZ Biotechnologies Company since June 2020 until March 2024. Since May 2020 he has served as Chairman of the Scientific Advisory Group for...

Leadership Team

NamePositionTenureCompensationOwnership
Paul B. Bolno
President11.2yrsUS$3.87m0.14%
€ 2.2m
Kyle B. Moran
CFO & Principal Accounting Officer4.2yrsUS$1.70m0.031%
€ 485.5k
Chandra Vargeese
Chief Technology Officer4.8yrsUS$1.78m0.15%
€ 2.4m
Erik Ingelsson
Chief Scientific Officerless than a yearno datano data
Kate Rausch
Head of Investor Relations5.8yrsno datano data
Linda Rockett
Senior VP & General Counsel8.8yrsno datano data
Christopher Francis
Senior VP of Corporate Development & Head of Emerging Areas8.1yrsUS$1.68m0%
€ 0
Daryn Lewis
Senior VP & Head of Human Resources2.1yrsno datano data
Sridhar Vaddeboina
Senior Vice President of Chemistry3.3yrsno datano data
Hsiu-Chiung Yang
Senior Vice President of Translational Medicine2.1yrsno datano data

4.5yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 1U5's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul B. Bolno
President10.8yrsUS$3.87m0.14%
€ 2.2m
Gregory L. Verdine
Director11.6yrsUS$170.74k0.020%
€ 308.5k
Mark H. Corrigan
Independent Director5.4yrsUS$194.74k0.078%
€ 1.2m
Christian O. Henry
Independent Chairperson8.3yrsUS$222.24k0.085%
€ 1.3m
Adrian G. Rawcliffe
Independent Director8yrsUS$188.74k0.085%
€ 1.3m
Peter Kolchinsky
Independent Director10.1yrsUS$170.74k0%
€ 0
Ken Takanashi
Independent Director12.6yrsUS$170.74k0%
€ 0
Heidi L. Wagner
Independent Director5.4yrsUS$185.74k0.078%
€ 1.2m
Aik Na Tan
Independent Director4.5yrsUS$172.24k0.069%
€ 1.1m

8.3yrs

Average Tenure

56yo

Average Age

Experienced Board: 1U5's board of directors are considered experienced (8.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/11 06:57
End of Day Share Price 2025/02/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Wave Life Sciences Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madison Wynne El-SaadiB. Riley Securities, Inc.
Steven SeedhouseCGS International
Whitney IjemGuggenheim Securities, LLC